

ESMO Investor call: accelerating our oncology pipeline

30 September 2019

Cautionary statement regarding forward-looking statements



This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for FY 2018. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our second quarter 2019 earnings release and Annual Report on Form 20-F for FY 2018.

All expectations and targets regarding future performance and the dividend should be read together with "Assumptions related to 2019 guidance and 2016-2020 outlook" on page 61 of our second quarter 2019 earnings release.

Accelerating our oncology pipeline

Dr Hal Barron
Chief Scientific Officer, President R&D



Results of PRIMA

Dr Antonio González-Martín
Head of Medical Oncology,
Clinica Universidad de Navarra



Putting PRIMA in context

Dr Hal Barron
Chief Scientific Officer, President R&D



Oncology strategy & data presentations at ESMO

Dr Axel Hoos
SVP, Oncology R&D



Building our in market oncology capabilities

Luke Miels
President, Global Pharmaceuticals



Q&A:

Christine Roth, SVP Global Oncology Therapy Area Head
Jenn Christensen, Medicine Development Lead niraparib
Dr Marc Ballas, Medicine Development Lead GSK'609

Science

X

Technology

X

Culture



**Strengthening our R&D
pipeline through a focus on
science related to the immune
system, the use of human
genetics, and advanced
technologies**

GSK Oncology: building on a strong foundation and investing for future performance



Smart business development

- Tesaro acquisition
 - Zejula expected to be supported by PRIMA
 - Dostarlimab expected to file by end 2019
 - Early stage IO pipeline
- Merck KGaA global alliance on bintrafusp alfa (M7824)

Strong internal R&D capabilities

- High calibre scientists within clinical teams
- Diverse portfolio of potentially transformational medicines
- Prioritisation and investment to accelerate promising assets including belantamab mafodotin, GSK'609

Strengthening in market operations

- Tesaro accelerated build of infrastructure
- Focus on recruiting the best sales force and medical talent
- Changed HCP engagement and sales rep incentivisation policies to be more competitive



17 assets in oncology pipeline

16 abstracts across 9 tumour types at ESMO

Further important data expected at ASH'19 and ASCO'20

3 oncology filings expected by end 2019

GSK Oncology: building on a strong foundation and investing for future performance



Smart business development

- Tesaro acquisition
- Zejula expected to be supported by PRIMA
- Dostarlimab expected to file by end 2019
- Early stage IO pipeline
- Merck KGaA global alliance on bintrafusp alfa (M7824)

Strong internal R&D capabilities

- High calibre scientists within clinical teams
- Diverse portfolio of potentially transformational medicines
- Prioritisation and investment to accelerate promising assets including belantamab mafodotin, GSK'609

Strengthening in market operations

- Tesaro accelerated build of infrastructure
- Focus on recruiting the best sales force and medical talent
- Changed HCP engagement and sales rep incentivisation policies to be more competitive

17 assets in oncology pipeline

16 abstracts across 9 tumour types at ESMO

Further important data expected at ASH'19 and ASCO'20

3 oncology filings expected by end 2019



Results of PRIMA

Dr Antonio González Martín, Head of Medical Oncology,
Clinica Universidad de Navarra

Niraparib is effective in recurrent ovarian cancer (*BRCAMut* and *BRCAwT*)



- Advanced ovarian cancer is a leading cause of cancer deaths in women with up to 85% recurrence after completion of standard first-line platinum-based chemotherapy¹
- Despite current options for maintenance treatment, there is still a high unmet need for many patients
 - **Olaparib**: limited to patients with *BRCA* mutations; ≈20% of OC patients²
 - **Bevacizumab**: limited use due to safety concerns and limited data in the growing number of patients receiving NACT
 - **Active surveillance**: many patients undergo watchful waiting following chemotherapy
- Niraparib was the first oral PARP inhibitor approved as maintenance for all patients with recurrent OC (*BRCAMut* and *BRCAwT*)
 - NOVA study demonstrated efficacy of niraparib maintenance after platinum CT in all biomarker populations: *gBRCAMut*: hazard ratio 0.27 (95% CI 0.17–0.41, $P < 0.0001$); homologous recombination deficient: hazard ratio 0.38 (95% CI 0.24–0.59, $P < 0.0001$) and non-*gBRCAMut*: hazard ratio 0.45 (95% CI 0.34–0.61, $P < 0.0001$)³
 - QUADRA study showed niraparib treatment benefit in patients with at least 3 prior therapies: *BRCAMut* 39% ORR, homologous recombination deficient 26% ORR, duration of response 9.4 months⁴

CI, confidence interval; CT, chemotherapy; NACT, neoadjuvant chemotherapy; mut, mutant; OC, ovarian cancer; ORR, objective response rate; PARP, poly (ADP-ribose) polymerase; wt, wild-type.

1. GLOBOCAN, 2018; 2. Moore, NEJM 2018; 3. Mirza, NEJM 2016; 4. Moore, Lancet Oncol 2019.

PRIMA was designed to address the unmet need in 1L advanced ovarian cancer



Hypothesis: PRIMA/ENGOT-OV26/GOG-3012 was designed to test the efficacy and safety of niraparib therapy after response to platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer, including those at high risk of relapse (ClinicalTrials.gov: NCT02655016)


Key inclusion criteria

- High grade serous or endometrioid pathology
- Stage III: PDS with visible residual disease post surgery, NACT, or inoperable
- Stage IV: PDS regardless of residual disease, NACT, or inoperable
- CR or PR following platinum first-line treatment
- Tissue for homologous recombination testing was required at screening (Myriad myChoice[®])

Key exclusion criteria

- Patients with Stage III disease who have had complete cytoreduction (i.e., no visible residual disease) after PDS

PRIMA trial design



PRIMA tissue test for homologous recombination



Testing for Homologous Recombination Deficiency (HRd) and Proficiency (HRp)


Next generation sequencing of DNA from tumor tissue (Myriad Genetics myChoice® Test)

Provides a score based on algorithmic measurement of 3 tumor factors:

- Loss of heterozygosity (LOH)
- Telomeric allelic imbalance (TAI)
- Large-scale state transitions (LST)

Homologous recombination status is determined by the following:


- HR-deficient tumors: Tissue test score ≥ 42 **OR** a *BRCA* mutation
- HR-proficient tumors: Tissue test score < 42
- HR-not-determined



HRD, homologous recombination deficient

¹<https://myriadmychoice.com/portfolio/ovarian-cancer/mychoice-hrd-ovarian-cancer/#result>

PRIMA enrollment and outcomes



Median follow up of 13.8 months

*19 patients (8 HRd) and 7 patients (5 HRd) discontinued due to other reasons in the niraparib and placebo arms, respectively.
AE, adverse event, HRd, homologous recombination deficient, PD, progression of disease

PRIMA patient characteristics and baseline demographics




Characteristic	Niraparib (n=487)	Placebo (n=246)	Overall (N=733)
Age, median (range), years	62 (32, 85)	62 (33,88)	62 (32, 88)
Weight, median, kg	66	66	66
Stage at initial diagnosis, n (%)			
III	318 (65)	158 (64)	476 (65)
IV	169 (35)	88 (36)	257 (35)
Prior NACT, n (%)			
Yes	322 (66)	167 (68)	489 (67)
No	165 (34)	79 (32)	244 (33)
Best response to platinum-based CT, n (%)			
CR	337 (69)	172 (70)	509 (69)
PR	150 (31)	74 (30)	224 (31)
Homologous recombination test status, n (%)			
HRd	247 (51)	126 (51)	373 (51)
<i>BRCAmut</i>	152 (31)	71 (29)	223 (30)
<i>BRCAw</i>	95 (20)	55 (22)	150 (20)
HRp	169 (35)	80 (33)	249 (34)
HRnd	71 (15)	40 (16)	111 (15)

- 35% of patients were Stage IV
- 99.6% with Stage III had residual disease post PDS
- 67% received NACT
- 31% achieved a PR to 1L CT
- 51% had HRd tumors
- 30% had *BRCAmut* tumors
- 34% had HRp tumors

1L, first-line; CR, complete response; CT, chemotherapy; HRd, homologous recombination deficient; HRp, homologous recombination proficient; HRnd, homologous recombination not determined; mut, mutation; NACT, neoadjuvant chemotherapy; PR, partial response; wt, wild-type.

PRIMA primary endpoint, PFS benefit in the HR-deficient population




57% reduction in risk of relapse or death with niraparib

	Niraparib (n=247)	Placebo (n=126)
Median PFS		
months (95% CI)	21.9 (19.3–NE)	10.4 (8.1–12.1)
Patients without PD or death (%)		
6 months	86%	68%
12 months	72%	42%
18 months	59%	35%

Niraparib	247	231	215	189	184	168	111	76	66	42	22	19	13	4	0
Placebo	126	117	99	79	70	57	34	21	21	11	5	5	4	1	0

CI, confidence interval; NE, not estimable; PD, progressive disease; PFS, progression-free survival.
Sensitivity analysis of PFS by the investigator was similar to and supported the BICR analysis.

PRIMA primary endpoint, PFS benefit in the overall population



38% reduction in risk of relapse or death with niraparib

	Niraparib (n=487)	Placebo (n=246)
--	-------------------	-----------------

Median PFS


months (95% CI)	13.8 (11.5–14.9)	8.2 (7.3–8.5)
-----------------	------------------	---------------

Patients without PD or death (%)

6 months	73%	60%
12 months	53%	35%
18 months	42%	28%

Niraparib	487	454	385	312	295	253	167	111	94	58	29	21	13	4	0
Placebo	246	226	177	133	117	90	60	32	29	17	6	6	4	1	0


PRIMA exploratory analysis, PFS benefit in pre-specified groups



PRIMA PFS benefit in biomarker subgroups




Homologous Recombination Deficient (HRd)



- Niraparib provided similar clinical benefit in the HRd subgroups (*BRCAmut* and *BRCAwt*)
- Niraparib provide clinically significant benefit in the HR-proficient subgroup with a 32% risk reduction in progression or death

PRIMA key secondary endpoint, overall survival (11% data maturity)



Pre-planned interim analysis of overall survival numerically favors niraparib over placebo:

- overall population 84% vs 77% alive at 2 years
- HR-deficient 91% vs 85% alive at 2 years
- HR-proficient 81% vs 59% alive at 2 years

PRIMA safety overview



Adverse Event, no. (%)	Niraparib (n=484)	Placebo (n=244)
Any TEAE	478 (98.8)	224 (91.8)
Grade ≥ 3	341 (70.5)	46 (18.9)
Led to treatment discontinuation	58 (12.0)	6 (2.5)
Led to dose reduction	343 (70.9)	20 (8.2)
Led to dose interruption	385 (79.5)	44 (18.0)
TEAEs leading to death	2 (0.4)	1 (0.4)

- TEAEs were manageable and consistent with the PARP inhibitor class
- Dose interruptions were similar to those in the previous niraparib trials
- Treatment discontinuation due to thrombocytopenia was 4.3%
- TEAEs leading to death were determined to be not treatment-related

- Available therapies and active surveillance do not address the high unmet need for many patients with newly diagnosed advanced ovarian cancer after platinum-based chemotherapy
- Niraparib therapy in patients with advanced ovarian cancer provided a clinically significant improvement in PFS after response to 1L platinum-based chemotherapy in **ALL** patients
 - PFS overall population: hazard ratio, 0.62; $p < 0.001$
 - PFS homologous recombination deficient: hazard ratio, 0.43; $p < 0.001$
 - PFS homologous recombination proficient: hazard ratio, 0.68; $p = 0.020$
- Niraparib is **the first** PARP-inhibitor to demonstrate benefit in patients across biomarkers subgroups after platinum-based chemotherapy in frontline, consistent with prior clinical studies of niraparib in recurrent ovarian cancer (NOVA and QUADRA)
- Patients with ovarian cancer at the highest risk of early disease progression (NACT, partial responders to 1L platinum chemotherapy) had significant benefit with niraparib therapy
- No new safety signals were observed, and quality of life was maintained on niraparib.
- Niraparib monotherapy after surgery and platinum-based chemotherapy could be an important new treatment option for patients



Putting PRIMA in context

Dr Hal Barron, Chief Scientific Officer and President R&D

Why was Tesaro a smart risk?



The questions:

1: Does Zejula offer a benefit to women with ovarian cancer with an HR deficiency (ie HRD positive) in the first line maintenance setting?

2: Does Zejula offer a benefit to all women with ovarian cancer in the first line maintenance setting?

The hypotheses:

PARP inhibitors have efficacy beyond gBRCA patients and benefit patients with other forms of HR defect

Patients with HR proficient tumours (HRD-) benefit from an alternative mechanism including immune activation through the STING pathway or PDL1 upregulation, for which Zejula would be a uniquely suitable PARP inhibitor as it has unique pharmacokinetic properties

Conclusions:

PRIMA met the primary endpoint with a highly statistically significant and clinically meaningful PFS improvement in both the HRD+ and all-comers populations

Caution needs to be taken when making cross trial comparisons, especially when patient populations vary



Hazard ratio better shows biological impact than mPFS

	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Stage III: visible residual disease <u>required</u> after PDS	YES	NO	NO	NO	YES	NO
Stage IV: inoperable disease	YES	YES	YES	YES	NO	NO
NACT permitted	YES	YES	YES	YES	NO	NO
<i>BRCAmut</i> only	NO	YES	NO	NO	NO	NO

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011

PDS: primary debulking surgery; NACT: neoadjuvant chemotherapy

Comparing PARPi and bevacizumab in 1L ovarian cancer



	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Overall population	0.62		0.59	0.68	0.73	0.87
HR deficient <i>BRCAmut</i> (~20% of patients*)	0.40	0.30	0.31	0.44	0.95	ND
HR deficient <i>BRCAwt</i> (~30% of patients*)	0.50		0.43	0.74 NS		ND
HR proficient <i>BRCAwt</i> (~50% of patients*)	0.68		0.92 NS	0.81 NS	0.71	ND

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011

* Patients with known BRCA and HR status

Comparing PARPi and bevacizumab in 1L ovarian cancer



First conclusion

	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Overall population	0.62		0.59	0.68	0.73	0.87
HR deficient <i>BRCAmut</i> (~20% of patients*)	0.40	0.30	0.31	0.44	0.95	ND
HR deficient <i>BRCAwt</i> (~30% of patients*)	0.50		0.43	0.74 NS		ND
HR proficient <i>BRCAwt</i> (~50% of patients*)	0.68		0.92 NS	0.81NS	0.71	ND

Aggregate data demonstrate that HR deficient (HRD+) patients benefit from a PARPi

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011

* Patients with known BRCA and HR status

Comparing PARPi and bevacizumab in 1L ovarian cancer



Second conclusion

	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Overall population	0.62		0.59	0.68	0.73	0.87
HR deficient <i>BRCAmut</i> (~20% of patients*)	0.40	0.30	0.31	0.44	0.95	ND
HR deficient <i>BRCAwt</i> (~30% of patients*)	0.50		0.43	0.74 NS		ND
HR proficient <i>BRCAwt</i> (~50% of patients*)	0.68		0.92 NS	0.81 NS	0.71	ND

Bevacizumab demonstrated no benefit in HR deficient (HRD positive) patients

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011

* Patients with known BRCA and HR status

Comparing PARPi and bevacizumab in 1L ovarian cancer



Third conclusion

	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Overall population	0.62		0.59	0.68	0.73	0.87
HR deficient <i>BRCAmut</i> (~20% of patients*)	0.40	0.30	0.31	0.44	0.95	ND
HR deficient <i>BRCAwt</i> (~30% of patients*)	0.50		0.43	0.74 NS		ND
HR proficient <i>BRCAwt</i> (~50% of patients*)	0.68		0.92 NS	0.81 NS	0.71	ND

Zejula is the only PARP inhibitor that demonstrated a benefit in HR proficient (HRD-) patients; bevacizumab showed a similar benefit

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011

* Patients with known BRCA and HR status

Comparing PARPi and bevacizumab in 1L ovarian cancer



	PRIMA ¹ niraparib	SOLO-1 ² olaparib	PAOLA-1 ³ bevacizumab +/- olaparib	VELIA ⁴ veliparib	GOG-218 ⁵ bevacizumab	ICON7 ⁶ bevacizumab
N	733	391	806	1140	1873	1528
Overall population	0.62		0.59	0.68	0.73	0.87
HR deficient <i>BRCAmut</i> (~20% of patients*)	0.40	0.30	0.31	0.44	0.95	ND
HR deficient <i>BRCAwt</i> (~30% of patients*)	0.50		0.43	0.74 NS		ND
HR proficient <i>BRCAwt</i> (~50% of patients*)	0.68		0.92 NS	0.81 NS	0.71	ND

Only Zejula demonstrated efficacy in all patient HR subgroups in first line

(1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011



* Patients with known BRCA and HR status

Could Zejula's unique PK profile explain the benefit in HRD- patients?



At steady state, the concentration of niraparib is higher in the tumour than the plasma

BRCAwT ovarian cancer model*



www.oncotarget.com


Oncotarget, 2018, Vol. 9, (No. 98), pp: 37080-37096

Research Paper


A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models

Kaiming Sun¹, Keith Mikule¹, Zebin Wang¹, Grace Poon¹, Aparajitha Vaidyanathan², Gillian Smith², Zhi-Yi Zhang¹, Jeffrey Hanke¹, Sridhar Ramaswamy¹ and Jing Wang¹

BRCAmut TNBC model**



BRCAwT ovarian model***



“Our results show that at steady state, tumor exposure to niraparib is 3.3 times greater than plasma exposure in tumor xenograft mouse models.

In comparison, the tumor exposure to olaparib is less than observed in plasma. In addition, niraparib crosses the blood-brain barrier and shows good sustainability in the brain, whereas sustained brain exposure to olaparib is not observed in the same models. Consistent with its favorable tumor and brain distribution, niraparib achieves more potent tumor growth inhibition than olaparib in BRCAwT models and an intracranial tumor model at maximum tolerated doses (MTD).”

Sun et al

Clinical confirmation of higher exposure to niraparib in tumour versus plasma in patients with breast cancer



211P

Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients with Breast Cancer


Laura Spring,¹ Ming Shan,² Minetta C. Liu,³ Erika Hamilton,⁴ Cesar A. Santa-Maria,⁴ Hanna Irie,⁴ Steven Isakoff,¹ James Reeves,⁷ Leif W. Ellisen,¹ Andre Liem,¹ Adriana Milillo Naraine,⁸ Julie Nangia,¹⁰ David Page,¹¹ Peng Pan,² Kaiming Sun,¹ Julie R. Graham,² Sebastian Hazard,² Hyo Han,¹

¹Massachusetts General Hospital, Boston, MA, USA; ²TESARO: A GSK Company, Waltham, MA, USA; ³Mayo Clinic, Rochester, MN, USA; ⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; ⁵Kaiser Permanente Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA; ⁶Wein School of Medicine at Mount Sinai, New York, NY, USA; ⁷Florida Cancer Specialists-South, Fort Myers, FL, USA; ⁸Pacific West Medical Group, Long Beach, CA, USA; ⁹Memorial Healthcare System, Hollywood, FL, USA; ¹⁰Baylor College of Medicine, Houston, TX, USA; ¹¹Hennepine County Medical Center, Portland, OR, USA; ¹²Duke Cancer Center/McIntire Outpatient Clinic, Tampa, FL, USA.

Background

- Niraparib is a selective oral poly(ADP-ribose) polymerase 1/2 inhibitor approved as maintenance treatment for patients with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy¹³
- Animal models revealed unique pharmacological properties of niraparib, including higher concentrations in tumors than in plasma (Figure 1)¹⁴
 - Higher niraparib tumor concentrations were associated with improved tumor control¹⁵
- Another poly(ADP-ribose) polymerase 1/2 inhibitor, olaparib, has demonstrated lower tumor

Figure 1. Steady-State Pharmacokinetics (PK) of Niraparib and Olaparib




Objective

- To analyze intra-tumoral niraparib concentration and compare niraparib tumor and plasma concentrations in patients with breast cancer

Methods

- Samples were collected from patients enrolled in an ongoing pilot study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment for HER2-negative, BRCA-mutated localized breast cancer (NCT03326607).
- Patients received oral niraparib 200 mg once daily for at least two 28-day cycles (Figure 2)
 - Tumor biopsies and plasma samples were obtained at the end of the second treatment cycle
 - At the time of this analysis, samples were available from 14 of the 21 enrolled patients
 - Tumor biopsies could not be collected from patients who did not have adequate tumor tissue (eg, with complete or near-complete response or a tumor too small to take a biopsy)
 - Additional plasma samples were collected on cycle 2/day 1 at 0, 2, and 4 hours post-dose to determine steady-state maximum concentration (C_{max})
- We used C_{max} to conservatively estimate the niraparib tumor-to-plasma ratio for those patients with missing matching plasma samples
- Niraparib concentrations in plasma and tumor samples for each patient were determined using validated liquid chromatography-tandem mass spectrometry methods

Figure 2. Study Design



Results

- Patient demographics and baseline characteristics are shown in Table 1

Table 1. Patient Demographics and Baseline Characteristics

Characteristic	Total (n=14)
Age, years	
Median	36.5
Mean	42.3
Min, max	21, 73
Age group, n (%)	
<35 years	12 (85.7)
≥35 years	2 (14.3)
ECOG performance status score, n (%)	
0	13 (92.9)
1	1 (7.1)
Stage at diagnosis, n (%)	
I-II	12 (85.7)
III	2 (14.3)
BRCA mutation status, n (%)	
BRCA1	10 (71.4)
BRCA2	3 (21.4)
BRCA1 and BRCA2	1 (7.1)
Hormone receptor status, n (%)	
HER2	11 (78.6)
ER and/or PR positive disease	3 (21.4)

Figure 3. Niraparib Plasma and Tumor Concentrations in Individual Patients




Table 2. Niraparib Concentrations in Plasma and Tumor

Patient number	Highest plasma nitrate concentration (from 0 to 24 h post-dose) (μM)	Nitrate concentration from C2003 plasma collected within plasma pmc	Nitrate concentration from C2003 urine (pmc)	Renal plasma nitrate concentration (pmc)
1	4260.82	1485.67	1604.56	11.2
2	1625.68	792.39	1040.09	34.7
3	3152.37	1020.15	1214.52	13.4
4	3152.37	1296.13	1296.13	<4.2
5	2049.34	1123.62	793.72	6.4
6	1465.32	1465.32	1020.15	<49.2
8	1632.49	887.66	793.72	81.5
9	1632.49	1020.15	1020.15	19.3
10	3495.70	1020.15	7020.03	<96.1
11	2029.59	1465.32	13319.49	<95.9
12	1468.15	1465.32	1465.32	<4.1
13	3495.70	3462.21	2893.95	8.5
14	1616.64		4082.92	9.5

Niraparib concentrations in tumors ranged from 46325 ± 42300 nM (mean ± SD), which is 35.8 ± 35.9 (mean ± SD)-fold higher than those in corresponding plasma samples after 2 months of niraparib treatment (Figure 3 and Table 2)

- Niraparib concentrations in plasma were within the reference range previously reported for a 210 mg daily dose in patients with solid tumors (steady-state C₁₂: 3160 ± 2790 nM, trough concentration (C_{min}): 1753 ± 1707 nM, mean ± standard deviation) [50]

Conclusions

- These results provide the first data of the intra-tumor concentration of niraparib in the clinical setting
- The concentration of niraparib was on average ~38-fold greater in tumor tissue than in plasma
- Confirms preclinical data that showed that tumor concentration is higher than in plasma, a unique property of niraparib
- Efficacy results will be reported at a future meeting

References

1. ZEJULAF [prescribing information]. Waltham, MA: TESARO; A GSK Company; 2019.
2. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/202044Orig1s01.pdf.
3. ZEJULAF [ZPAR summary for the public]. Accessed 5 Aug 2019; https://www.ema.europa.eu/en/documents/product-information/zejula-product-information_en.pdf.
4. van Ardel L, et al. Cancer Chemother Pharmacol. 2018;81(1):39-46.
5. Sun K, et al. Oncotarget. 2018;9(50):27580-96.
6. Sundred N, et al. Invest New Drugs. 2012;31(4):549-66.
7. Banerji UC, et al. Leukal Oncol. 2013;16:885-92.

Acknowledgments

The authors thank the patients and their families for their participation in this study, as well as the study teams at each of the study sites. Writing and editorial support, funded by TESARO: A GSK Company (Waltham, MA, USA) and coordinated by Teodoro O. Faustino, PhD, of TESARO, were provided by Eric Scocchia, PhD, and Frederique H. Evans, MSc, of Ashfield Healthcare Communications (Middletown, CT, USA) and Adrienne M. Schreiber of TESARO.

Disclosures

Laura Spring reports no conflicts of interest. Activate QR code for a complete list of author disclosures.



GSK Oncology: data at ESMO

ICOS: results from INDUCE-1

Axel Hoos, SVP Oncology R&D

GSK Oncology: building on a strong foundation and investing for future performance



Smart business development

- Tesaro acquisition
- Zejula expected to be supported by PRIMA
- Dostarlimab expected to file by end 2019
- Early stage IO pipeline
- Merck KGaA global alliance on bintrafusp alfa (M7824)

Strong internal R&D capabilities

- High calibre scientists within clinical teams
- Diverse portfolio of potentially transformational medicines
- Prioritisation and investment to accelerate promising assets including belantamab mafodotin, GSK'609

Strengthening in market operations

- Tesaro accelerated build of infrastructure
- Focus on recruiting the best sales force and medical talent
- Changed HCP engagement and sales rep incentivisation policies to be more competitive

17 assets in oncology pipeline

16 abstracts across 9 tumour types at ESMO


Further important data expected at ASH'19 and ASCO'20

3 oncology filings expected by end 2019

Oncology R&D: strategy and scientific focus



Maximise patient survival through transformational medicines



Data at ESMO: oncology clinical pipeline



Representing 8 clinical programs across four focus areas




GSK'609 ICOS receptor agonist



Differentiated MOA with encouraging clinical data at ESMO 2019

Target	• ICOS, a member of the CD28 family of co-stimulatory receptors, has a pivotal role in the proliferation, differentiation, survival, and function of T cells • Highly upregulated upon T-cell receptor stimulation¹ and is expressed on tumour infiltrating lymphocytes in many tumours² • Consistent with CTLA-4 and PD-1 blockade, ICOS agonism is anticipated to modulate T-cell dynamics resulting in prolonged control of tumour growth kinetics and survival in patients
Agent	• Humanised IgG4 antibody selected for its potent binding, agonist activity through the human ICOS receptor and low/no T-cell depleting effects via antibody-dependent cellular toxicity • Anti-tumour activity observed with an ICOS agonist is further enhanced in combination with CTLA-4 and PD-1 blockade in non-clinical models^{3,4} ICOS agonist treatment led to upregulation of PD-1/PDL-1 expression in these models³ • RNA-sequencing data shows strong correlation of ICOS and PD-L1 in solid tumours, further supporting clinical evaluation of this combination⁴
Status	• Clinical activity observed with both monotherapy and PD-1 combination; HNSCC data presented at ESMO September 2019 • Pivotal studies in HNSCC to commence by early 2020 • Other studies ongoing including novel combinations across tumours




APC, antigen-presenting cell; CXCR5, C-X-C motif chemokine receptor 5; ICOS-L, ICOS ligand; IFN-γ, interferon gamma; MHC, major histocompatibility complex

ICOS: checkpoint modulation beyond PD-1



Association with successful IO mechanisms of action increases clinical PoS

Agonist receptor families



Mayes, Hance and Hoos, Nature Reviews Drug Discovery 2018

CTLA-4 and PD-1 Kinetics of Clinical Activity Melanoma and Head & Neck Cancer

	ORR	DOR	OS @ 2y
Ipilimumab (CTLA-4) Melanoma 2L	11% (same as CTX)	>2y	22%
Pembrolizumab (PD-1) HNSCC 1L	17% vs 36% CTX	23mo vs 4mo	28% Vs 17%
Pembrolizumab (PD-1) + CTX HNSCC 1L	36% vs 36% CTX	7mo vs 4mo	31% vs 17%


Low ORR, strong OS benefit relative to CTX

Hodi et al. NEJM 2010; Rischin et al., ASCO 2019


GSK'609: first time monotherapy activity has been seen with an ICOS agonist in multiple tumour types



Best tumour response HNSCC



Change from baseline in tumour measurement by dose level (irRECIST)




Monotherapy activity with durable response across multiple tumour types

irCR, immune-related complete response; irPD, immune-related progressive disease; irPR, immune-related partial response; irSD, immune-related stable disease; pembro, pembrolizumab
 ESMO 2019 poster: "Inducible T-cell co-stimulatory (ICOS) receptor agonist, GSK3359609, alone and in combination with pembrolizumab: preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)"

GSK'609: early data point to ORR of 24% in combination with pembrolizumab with durable responses




Best tumour response



Dose*: ■ GSK609 0.3mg/kg + pembro 200mg ■ GSK609 1mg/kg + pembro 200mg

*Patients (non-randomised) from both DE and CE phases included; *patients received GSK3359609 0.3 mg + pembro 200 mg

Change from baseline in tumour measurement by dose level (irRECIST)



Dose†: ■ GSK609 0.3mg/kg + pembro 200mg ■ GSK609 1mg/kg + pembro 200mg

→ treatment ongoing; †patients from both DE and CE phases included.
Dashed lines are guidelines for determining level of response. Breaks in y-axes inserted to facilitate data interpretation.

Durable response in combination cohort with all responding patients maintaining benefit for ≥ 6 months


irCR, immune-related complete response; irPD, immune-related progressive disease; irPR, immune-related partial response; irSD, immune-related stable disease; pembro, pembrolizumab

ESMO 2019 poster: "Inducible T-cell co-stimulatory (ICOS) receptor agonist, GSK3359609, alone and in combination with pembrolizumab: preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)"

GSK'609: responses not correlated to PD-L1 expression suggesting ICOS agonist activity



irRecist confirmed response versus CPS score




BOR, best overall response; CPS, combined positive score; CR, complete response; irRECIST, immune-related Response Evaluation Criteria In Solid Tumours; PD, progressive disease; PR, partial response; SD, stable disease

A majority of patients with responses and stable disease have low PD1 expression supporting evidence of ICOS agonist activity


GSK'609: safety and tolerability consistent with results previously reported



Monotherapy cohorts (Part 1A and 1B, N=22)



Combination cohort (Part 2A and 2B, N=58)



Treatment-related AEs in patients with HNSCC across all study cohorts in the monotherapy (n=22) and combination populations (n=58) were consistent with that previously reported

GSK'609: progressing to advanced trials and novel combinations



Solid tumours

				Study start	Read-out
INDUCE-1	POC	Relapsed/refractory selected solid tumours	Open label dose escalation and expansion study of GSK'609 monotherapy and combination with pembrolizumab n= >500	2016	NA

HNSCC

recurrent or metastatic

INDUCE-2	POC	Relapsed/ refractory HNSCC	Open label dose escalation and expansion study of GSK'609 in combination with tremelimumab N=114	Dec'18	2020
INDUCE-3	pivotal	First line PD-1 positive recurrent or metastatic HNSCC	Randomised, double blind, adaptive study of GSK'609 or placebo in combination with pembrolizumab	End 2019	2023

55k
patients*

NSCLC

relapsed/ refractory advanced

ENTRÉE	platform	Relapsed/ refractory NSCLC	Open label platform study of novel regimens of GSK'609 mono and combo versus SoC n=105	Jan'19	2020
---------------	----------	----------------------------	---	--------	------

130k
patients*

* Drug-treated patients. Source: Kantar Patient Matrix for US, EU5 and Japan in 2019, September 2019

POC = proof of concept; HNSCC = head and neck squamous cell carcinoma; SoC = standard of care; NSCLC = non small cell lung cancer



Building our oncology commercial capabilities

Luke Miels, President Global Pharmaceuticals

GSK Oncology: building on a strong foundation and investing for future performance



Smart business development

- Tesaro acquisition
- Zejula expected to be supported by PRIMA
- Dostarlimab expected to file by end 2019
- Early stage IO pipeline
- Merck KGaA global alliance on bintrafusp alfa (M7824)

Strong internal R&D capabilities

- High calibre scientists within clinical teams
- Diverse portfolio of potentially transformational medicines
- Prioritisation and investment to accelerate promising assets including belantamab mafodotin, GSK'609

Strengthening in market operations

- Tesaro accelerated build of infrastructure
- Focus on recruiting the best sales force and medical talent
- Changed HCP engagement and sales rep incentivisation policies to be more competitive

17 assets in oncology pipeline

16 abstracts across 9 tumour types at ESMO

Further important data expected at ASH'19 and ASCO'20

3 oncology filings expected by end 2019

Building our oncology commercial capability



Improved engagement with HCPs

Updated HCP engagement policies to improve how we help prescribers understand new data and clinical experience with our innovative products

Attracting and retaining the best sales force talent

Competitive sales force incentives for Specialty area in place to recruit, motivate and retain sales teams with the right levels of expertise and experience

Seamless execution across functions and in markets

Aligned efforts to ensure launch readiness for exciting oncology launches and drive value for patients and shareholders

3 potential oncology launches in 2020

Zejula 1L maintenance therapy (PRIMA) presented at ESMO 2019

- Significantly improved PFS in the overall population
- Filing expected by end 2019

Belantamab mafodotin (BCMA ADC) 4L Multiple Myeloma (DREAMM-2) to be presented at an upcoming medical congress

- Study met primary objective and demonstrated clinically meaningful ORR
- Filing expected by end 2019

Dostarlimab (PD-1) in recurrent endometrial cancer (GARNET) with interim data presented at SGO 2019


- Filing expected by end 2019

Expect increase in use of PARPs following ESMO data with 1L monotherapy taking leading share



PARPs underutilised in 1L and 2L ovarian cancer

Utilisation % of eligible maintenance patients (US)



Avastin combination presents challenges

- Combination of PARP + Avastin increases cost, toxicity and administration challenges in maintenance setting
- Avastin currently used in <20% of 1L maintenance ovarian cancer patients in US; <50% EU and Japan*
- May limit Avastin as option for 2L
- Avastin has not demonstrated overall survival benefit in 1L

Zejula uniquely positioned with PRIMA data

- Demonstrated benefit in all comers population including HRD negative patients
- Pre-planned interim analysis of overall survival numerically favours Zejula over placebo
- Unique PK properties with preclinical evidence suggesting greater tumour penetration*
- Oral, once daily monotherapy with low drug interactions – key in maintenance setting

Flatiron Health EMR data through Jul 31, 2019

FL Eligibility criteria:

- Patients who received 4-9 cycles of platinum for 2L+ treatment
- **Watch and wait % changes 3-5% with variation in:
 - duration between last platinum administration date and sample end date
 - # of administered platinum cycles

*Flatiron Health data

*Sun et al, Oncotarget, 2018, Vol. 9, (No. 98), pp: 37080-37096

Q&A



Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He is a member of the Board and the Corporate Executive Team.

His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.

Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation. Hal is Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is also a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet Inc.

Hal holds a Bachelor of Science degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.



Dr González-Martín graduated in medicine at University of Navarra in Pamplona, and subsequently trained in medical oncology at University Hospital Ramón y Cajal in Madrid from 1994 to 1997. During part of 1997 he attended as an observer to The Mount Sinai School of Medicine in New York. He joined as staff member of the Medical Oncology Service at University Hospital Ramón y Cajal in 1998. From January 2009 he gained the position of Head of Medical Oncology Department at MD Anderson Cancer Center Madrid, an affiliate institution of MD Anderson in Houston. He recently moved to Clinica Universidad de Navarra as head of Medical Oncology and co-director of the Oncology Department. He is Associate Professor at Medicine at Francisco de Vitoria University in Madrid and Adjunct Professor at University of Texas (TX, USA). He got the PhD degree at Francisco de Vitoria University in April 2018.

He specialises in the treatment of gynaecological and breast cancer and is the chairman of GEICO. He is also the representative of GEICO in ENGOT, and the current President of this Group. In addition, he is one of the representatives of GEICO in Gynecologic Cancer InterGroup, an international organisation for trials and treatment of gynaecological cancers, and by now is the chair of the ovarian cancer committee. He was also a member of the board of the Spanish Society of Medical Oncology, and member of GEICAM and SOLTI breast cancer cooperative groups.

He has several relevant publications in the field of gynaecological and breast cancer. He is considered an expert in ovarian and breast cancer and has lectured widely on these areas of interest.



Axel is SVP, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GSK, responsible for discovery and development in Oncology. As R&D governance chair he oversees technical and funding review committees. Axel also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute, a Global Health organization, Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium and Scientific Advisory Board Member of the Cancer Research Institute. Through his leadership a paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology (Nat. Rev. Drug Discovery 2016, 15(4):, 235-47).

Previously, Axel was the Global Medical Lead in Immunology/Oncology at BMS where he developed Yervoy (Ipilimumab), the first life-extending therapy and the first checkpoint inhibitor drug in Immuno-Oncology. The discovery of ipilimumab's scientific mechanism was honored with the Nobel prize for Physiology or Medicine to Dr. James Allison in 2018. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.



Luke joined GSK as President, Global Pharmaceuticals in September 2017. He is a member of the Corporate Executive Team.

At GSK, he is responsible for commercialising a portfolio of medicines and vaccines with annual sales of more than £20 billion and operations in over 100 markets. His previous role was Executive Vice President of AstraZeneca's European business and, prior to that, Executive Vice President of Global Product and Portfolio Strategy, Global Medical Affairs and Corporate Affairs.

Luke joined AstraZeneca from Roche, where he was Regional Vice President Asia Pacific for the Pharmaceuticals Division. Before then, he held roles of increasing seniority at Sanofi-Aventis in Asia and the US. He also co-led the US integration of Sanofi and Aventis. Prior to that, he held general management roles in Thailand and New Zealand, following his entry into the industry in Australia.

He holds a Bachelor of Science degree in Biology from Flinders University in Adelaide and an MBA from the Macquarie University, Sydney.



Christine re-joined GSK as SVP, Global Oncology Therapy Area Head in December 2017, reporting to Luke Miels. As the global commercial lead for oncology, Christine is a member of the Pharmaceutical Leadership Team, Forecast Review Committee, Research Investment Board, Development Review Board, and Global Pharmaceutical Leadership Team.

After beginning her career as a scientist, Christine joined BMS and progressed through commercial leadership roles in multiple therapeutic and functional areas. Together with Axel Hoos, she was a pioneer in Immuno-Oncology, serving as the commercial lead for the first approved I-O therapy, Yervoy (ipilimumab) and working on BMS's String of Pearls strategy which led to the acquisition of Medarex and the first PD-1, Opdivo.

Christine was delighted to return to GSK and partner again with Axel and the GSK Oncology team to build a new and improved, world-class oncology organization.



Jennifer completed her masters degree in Organic Chemistry from Brandeis University, Massachusetts. She has worked at a number of biotech companies including Tesaro, Xanthus/ Antisoma and Datide Research Laboratories.

Jennifer joined Tesaro in 2011 to initially lead the Varubi programme and is currently the medical development lead for Zejula (niraparib) in ovarian cancer



Marc S Ballas, MD, MPH is an Albert Einstein School of Medicine trained physician who completed his medical oncology/hematology at NIH and practiced as Assistant Professor at NYU Langone School of Medicine before joining the pharmaceutical industry.

Early on, he has been involved in the immune-oncology field working on late stage development of ipilimumab in small cell lung cancer, durvalumab in locally advanced and adjuvant non-small cell lung cancer.

Marc is currently the medical development lead for the GSK'609 ICOS agonist across solid tumors.